| Prev Close: | 83.37 |
|---|---|
| Open: | 80.17 |
| Bid: | 83.36 |
| Ask: | 83.44 |
| 1y Target Est: | N/A |
| Beta: | N/A |
| Next Earnings Date: | N/A |
| Day's Range: | 80.10 - 83.69 |
|---|---|
| 52wk Range: | 18.32 - 83.69 |
| Volume: | 3,946,953 |
| Avg Vol (3m): | 13,616 |
| Market Cap: | 110.33B |
| P/E (ttm): | 22.29 |
| EPS (ttm): | 3.74 |
| Div & Yield: | N/A (N/A) |
Headlines
- ADR REPORT-ECB rate cut, jobless claims data lift ADRsat Reuters(Thu 1:26PM EDT)
- [$$] Sanofi's Slump Should be Short-Livedat The Wall Street Journal(Thu 1:22PM EDT)
- UPDATE 1-Shire cuts sales forecast as some drugs miss Q1 targetsat Reuters(Thu 8:30AM EDT)
- Sanofi SA Earnings Call scheduled for 8:30 am ET todayCCBN(Thu 8:30AM EDT)
- Q1 2013 Sanofi SA Earnings Release - 01:30 am ETCCBN(Thu 7:07AM EDT)
- Sanofi says to step up development of new diabetes deviceat Reuters(Thu 6:51AM EDT)
- Zealand Gains as Sanofi Will Speed Up Lyxumia: Copenhagen Moverat Bloomberg(Thu 5:07AM EDT)
- BRIEF-Sanofi opens down 3.7 pct after Q1 results missat Reuters(Thu 3:00AM EDT)
- French and Benelux stocks-Factors to watch on May 2at Reuters(Thu 2:28AM EDT)
- UPDATE 1-Sanofi Q1 misses forecasts on patent losses, forexat Reuters(Thu 2:24AM EDT)
- Sanofi Q1 2013 - Interview with CFO Jérôme ContamineBusiness Wire(Thu 1:45AM EDT)
- Sanofi Q1 misses forecasts, sees growth return in H2at Reuters(Thu 1:34AM EDT)
- Sanofi First-Quarter Profit Plunges 34%, Hurt by Genericsat Bloomberg(Thu 1:30AM EDT)
- Amgen Drugs May Boost Survival During a Nuclear Attackat Bloomberg(Wed, May 1)
- Drugs from Amgen, others assessed by FDA as radiation treatmentsat Reuters(Wed, May 1)
Press Releases
- Sanofi Q1 2013 - Interview with CFO Jérôme ContamineBusiness Wire(Thu 1:45AM EDT)
- Once-daily AUBAGIO® Delayed Onset of Clinically Definite Multiple Sclerosis (MS) in TOPIC StudyBusiness Wire(Thu, Apr 25)
- Genzyme Convenes 13th European Fabry Disease RoundtableBusiness Wire(Thu, Apr 18)
Reports
- Sanofi - SWOT, Strategy and Corporate Finance ReportDatamonitor(Mar 29)